[9] Nakajima N, Oguchi M, Kumai Y, et al. Clinical outcomes and prognostic factors in patients with stage II-III breast cancer treated with neoadjuvant chemotherapy followed by surgery and postmastectomy radiation therapy in the mod- ern treatment era[J]. Adv Radiat Oncol, 2018, 3(3): 271...
BREAST cancer treatmentKAPLAN-Meier estimatorBREAST cancer surgeryHER2 proteinObjective: Neoadjuvant chemotherapy (NAC) in breast cancer (BC) is being considered for a broader range of cases, including locally advanced tumors and situations where downstaging could r...
The proliferation marker Ki-67 is one of the most controversially discussed parameters for treatment decisions in breast cancer patients. The purpose of th
值得一提的是,该研究成果《Revolutionizing breast cancer Ki‑67 diagnosis: ultrasound radiomics and fully connected neural networks (FCNN) combination method》已在国际知名SCI期刊《Breast Cancer Research and Treatment》(影响因子3.0,中科院分区3区)上发表,获得了学术界的广泛认可。
ConclusionThe molecular classification with Ki-67 is better to predict breast cancers responsiveness to NAC than the molecular classification without Ki-67. KEYWORDS: Carcinoma, ductal, breast;Antineoplastic combined chemotherapy protocols;Ki-67 antigen;Treatment outcome;Molecular typing Corresponding author: ...
[1]Scholzen T,Gerdes J.The Ki-67 protein:from the known and the unknown.J Cell Physiol.2000;182(3):311-322. [2]Heinzelmann-Schwarz VA,Jäger W.Ki-67 expression pattern and its relevance for endocrine resistance in breast cancer.Pathology.2019;51(2):127-128。
EDITORIALShould Ki-67 be adopted to select breast cancer patients for treatmentwith adjuvant abemaciclib?On 12 October 2021, the US Food and Drug Administration(FDA) approved the cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor abemaciclib for the adjuvant treatment of hor-mone receptor-positive...
关键词: 超声检查;三阴性乳腺癌;新辅助化疗;Ki-67;病理完全缓解 ABSTRACT ObjectiveTo investigate the value of ultrasound and Ki-67 for early predicting pathological complete response (pCR) of triple negative breast cancer(TNBC) after neoadjuvant chemotherapy (NAC). MethodsRetrospective analysis was perform...
Ki-67 is a prognostic parameter in breast cancer patients: results of a large population-based cohort of a cancer registry The proliferation marker Ki-67 is one of the most controversially discussed parameters for treatment decisions in breast cancer patients. The purpose of th... EC Inwald,M...
One hundred twenty patients diagnosed with invasive breast cancer and treated with neoadjuvant chemotherapy (NAC) between 2002 and 2013 were retrospectively recruited to this study. The optimal cut-off value for Ki-67 labeling index (LI) to discriminate response to treatment was assessed by receiver...